Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer - OncLive

OncLive

Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer OncLive Treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and double 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma ... Nivolumab demonstrates efficacy in recurrent, metastatic SCCHNHealio all 2 news articles »

from squamous cell carcinoma via ok on Inoreader http://ift.tt/23X7Pq6
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/23IpwNv
via IFTTT